EU approves Opdivo-Yervoy combo for colorectal cancer - Investing.com
Bristol Myers Squibb announces European Commission approval of Opdivo and Yervoy as first-line treatment for MSI-H/dMMR metastatic colorectal cancer, based on Phase 3 CheckMate -8HW trial results showing 79% reduction in disease progression or death risk compared to chemotherapy. The approval extends across all 27 EU member states, Iceland, Liechtenstein, and Norway.
Highlighted Terms
Bristol Myers Squibbcertain advanced solid tumorsYervoyEuropean Commissionmicrosatellite instability-high (MSI-H)colorectal cancerROS1-positive advanced non-small cell lung cancerAlzheimer'sOpdivomismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC)schizophreniaCobenfyrepotrectinibKaruna TherapeuticsAmerican Society of Clinical Oncology Gastrointestinal Cancers Symposium
Related News
EU approves Opdivo-Yervoy combo for colorectal cancer - Investing.com
Bristol Myers Squibb announces European Commission approval of Opdivo and Yervoy as first-line treatment for MSI-H/dMMR metastatic colorectal cancer, based on Phase 3 CheckMate -8HW trial results showing 79% reduction in disease progression or death risk compared to chemotherapy. The approval extends across all 27 EU member states, Iceland, Liechtenstein, and Norway.